With all the advances in medicine and medical treatments, MDR bacteria remains one of the greatest threats in healthcare systems. The rates of AMR (antimicrobial resistance) organisms continues to increase globally despite the efforts to combat. WHO has declared that AMR is one of the top 10 global public health threats facing humanity with tremendous financial burden. And in the published WHO list of priority organisms for research and therapeutic development we see that many gram negative bacteria came on the top of the list with ( CRE Acinetobacter, Pseudomonas, and Enterobacteriaceae ) being the most critical group.
Many studies showed significant changes in resistance patterns across different micro-organisms, with higher rates of morbidity and mortality. Choices of antibiotics now depends on the local resistance patterns, hence it’s crucial to monitor the trends in resistance in order to guide patient management.
We lack enough data in this region when it comes to MDR bacterial infection, This knowledge is extremely important, and can improve the local and national guidelines approach, support the existing AMS programs, and encouraging hospitals to prioritize infection control and AMS interventions. And most importantly opens the doors to introduce new novel antimicrobials to help with the fight against MDR infections.
In this presentation, we will review available data regarding MDR trends in the GCC/Arab countries, how the whole picture is changing through the years, and what are the efforts to combat resistance ( what has been done, and what needs to be done ) . And since the fight against MDR organisms is global, we can all learn from others experiences.
Audience take away:
- Exploring the trends in resistance from different geographical regions , and how resistance can change over the years, this can give an idea of what others can face in the future
- Explore new antimicrobial stewardship interventions that has been used in those regions , some can be adapted , what works and what is not working.
- Highlights the importance of surveillance and updating antimicrobial guidelines